An observational study in Osteoporosis Secondary and Breast Cancer Females, sponsored by Regina Elena Cancer Institute. Recruiting at 2 sites in Italy. Open to female participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by Regina Elena Cancer Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Breast Neoplasms by Regina Elena Cancer Institute — 7 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Regina Elena Cancer Institute.
Among the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute, this one is the 6th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2025, is one of 12 observational ones, and was the 15th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
Regina Elena Cancer Institute · Sites in Italy
Ages 18+ · Women only
Regina Elena Cancer Institute · Sites in Italy
Ages 18+ · Women only
Regina Elena Cancer Institute · Sites in Italy
Ages 18+ · Women only · Healthy volunteers
Regina Elena Cancer Institute · Sites in Italy
Women only
Regina Elena Cancer Institute · Sites in Italy
Ages 25–45 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 35 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 134 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 104 across the 3 interventional studies, 134 across the 11 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regina Elena Cancer Institute is the lead sponsor of 95 studies on the registry; 51 are open to participants now.
1 of the studies in Breast Neoplasms by Regina Elena Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07256769Regina Elena Cancer InstituteVitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis | 2027-09-29 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In women with breast cancer undergoing adjuvant hormone therapy, the marked tissue hypoestrogenism induced by therapy with aromatase inhibitors and/or tamoxifen ± GnRH analogues causes a significant acceleration in bone mass loss, with a consequent increased risk of fracture from the first year of therapy. It is therefore essential to start treatment with antiresorptive drugs and calcium and vitamin D supplementation. It has been hypothesized that vitamin K and α-lactalbumin have an effect in improving the absorption of calcium and vitamin D. In addition, vitamin K promotes gamma-carboxylation of osteocalcin, causing its activation and leading to increased incorporation of hydroxyapatite into the bone, resulting in increased calcium uptake from the blood and other tissues. Studies have reported that a combination of alendronate and vitamin K2 can lead to a decrease in the ratio of uncarboxylated osteocalcin to carboxylated osteocalcin, contributing to an increase in BMD, especially in the femoral neck. α-lactalbumin is able to increase the bioaccessibility of calcium due to its ability to prevent its precipitation at the neutral pH present in the absorptive tracts of the small intestine. Furthermore, α- lactalbumin has a binding site for vitamin D3, and the complexes formed by monomers of this protein and vitamin D have shown good stability in the presence of high vitamin concentrations. Inositol is a carbohydrate structurally similar to glucose which, in its isomeric form D-chiro-inositol, acts on bone remodeling by blocking the activation of osteoclasts through inhibition of the binding of RANK-L to its receptor present on pre-osteoclasts. Our hypothesis is that the use of the combination of vitamin K, α- lactalbumin, and D-chiro-inositol should improve the intestinal absorption of calcium and vitamin D, increasing the percentage of patients able to normalize serum levels of vitamin D and urinary calcium excretion (as a parameter of adequate calcium intake). This aspect, together with the direct effect of these components on bone remodeling, could enhance the anti-resorptive effect of standard therapy with bisphosphonates, improving the quantitative and qualitative parameters of bone. Therefore, we design a prospective randomized pilot study to assess efficacy of the combination of vitamin K, α-lactalbumin, and D-chiro-inositol, comparing patients with standard therapy and patients treated with Synostea®
Recommendations regarding the ideal daily intake of calcium and vitamin D vary based on the anthropometric characteristics and comorbidities of patients. An adequate level of these two nutrients is recommended especially in patients undergoing treatment with anti-resorptive drugs used for both preventive and therapeutic purposes in osteoporosis. This occurs in women with breast cancer, in whom the marked tissue hypoestrogenism induced by adjuvant therapy (aromatase inhibitors and/or tamoxifen ± GnRH analogues) causes a significant acceleration in bone loss (CTIBL-Cancer Treatment-Induced Bone Loss), with a consequent increased risk of fracture from the first year of therapy. It is therefore essential to start treatment with antiresorptive drugs and calcium and vitamin D supplementation in order to safeguard bone health and prevent secondary osteoporosis.
Optimal serum concentrations of calcium and vitamin D play a central role in bone health, but insufficient intake can depend on numerous factors, including diet and the presence of other nutrients, as well as the body's ability to absorb them effectively. It has been hypothesized that vitamin K and α-lactalbumin improve the absorption of calcium and vitamin D. Vitamin K is a fat-soluble vitamin that comes in various forms, including vitamin K2 (menaquinone), which is involved in bone remodeling. It promotes gamma-carboxylation of osteocalcin, causing its activation and leading to increased incorporation of hydroxyapatite into bone, resulting in increased uptake of calcium from the blood and other tissues. High levels of the uncarboxylated form of osteocalcin, which is found in cases of vitamin K deficiency, have been associated with an increased risk of fractures despite adequate therapy with oral bisphosphonates. Studies have reported that a combination of alendronate and vitamin K2 can lead to a decrease in the ratio of uncarboxylated osteocalcin to carboxylated osteocalcin, contributing to an increase in BMD, especially in the femoral neck, thus reducing the risk of fragility fractures. α-Lactalbumin is a small acidic protein that has a binding site with high affinity for Ca++. The bioaccessibility of Ca++, i.e., the amount of micronutrient potentially available for absorption in the human body, depends on the amount of soluble calcium released from food processing during digestion. It has been hypothesized that binding to peptides such as α-lactalbumin may increase bioaccessibility due to its ability to prevent precipitation at the neutral pH present in the absorptive tracts of the small intestine. In addition, α-lactalbumin has a binding site for vitamin D3, and complexes consisting of monomers of this protein and vitamin D have shown good stability in the presence of high vitamin concentrations. It is also known from in vitro studies that α-lactalbumin can improve the intestinal absorption of D-chiro-inositol by as much as 10 times compared to the absence of this protein in the intestine.
The combination of vitamin K, α-lactalbumin, and D-chiro-inositol should improve the intestinal absorption of calcium and vitamin D, increasing the percentage of patients able to achieve normalization of serum vitamin D levels and urinary calcium excretion (understood as a parameter of adequate calcium intake). This aspect, together with the direct effect of these components on bone remodeling, could enhance the antiresorptive effect of standard bisphosphonate therapy, improving the quantitative and qualitative parameters of bone.
Inositol is a carbohydrate structurally similar to glucose which, in its D-chiro-inositol isomeric form, acts on bone remodeling by blocking the activation of osteoclasts through inhibition of the binding of RANK-L to its receptor present on pre-osteoclasts.
Therefore, we design a prospective randomized pilot study aims to evaluate the effect of synergistic effect of vitamin K, α-lactalbumin and D-chiro-inositol supplementation compared to standard therapy with calcium carbonate and vitamin D alone on calcium-phosphorus metabolism parameters and bone mineral density in patients with breast cancer treated with alendronate for the prevention of bone damage from hormone therapy.
Adult women (aged between 35 and 70) with breast cancer undergoing treatment with aromatase inhibitors or tamoxifen + GnRH analogues or aromatase inhibitors + GnRH analogues, and about to start treatment with oral bone resorption inhibitors (alendronate), and meeting the other criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard therapy
Dietary Supplement: Group 1: calcium carbonate/cholecalciferol
Synostea®
Dietary Supplement: Group 2: Synostea® (calcium carbonate/cholecalciferol/vitamin K/α-lactalbumin/ d-chiro-inositol)
Drug pages: Calcium CarbonateStudies of Calcium CarbonateCalcium Carbonate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Intake of calcium carbonate 500 mg + cholecalciferol 2000 IU
Intake of Synostea® : calcium carbonate 400 mg + cholecalciferol 2000 IU + vitamin K (menaquinone 50 μg) + α-lactalbumin (30 mg) + d-chiro-inositol (150 mg)
Evaluation of differences in mean vitamin D levels after six months in patients treated with calcium carbonate + cholecalciferoland patients treated with calcium carbonate + cholecalciferol + vitamin K + α-lactalbumin + d-chiro-inositol
Change in mean vitamin D levels in the two treatment groups after 6 months of therapy
Time frame: 6 months
Evaluation of the differences in Hip Bone Mineral Density by D-XA between groups
To evaluate difference in the change from baseline in hip BMD (Bone Mineral Density) by dual x ray absorptiometry after 12 months between the 2 groups (standard vitamin d and calcium supplementation vs Synostea®)
Time frame: 12 months
Evaluation of the differences in lumbar fragility score by Radiofrequency Echographic Multi Spectrometry between groups
To evaluate difference in the change from baseline in lumbar fragility score by Radiofrequency Echographic Multi Spectrometry after 12 months between the 2 groups (standard vitamin d and calcium supplementation vs Synostea®)
Time frame: 12 months
Evaluation of the differences in serum levels of total calcium betweeeng groups after 12 months
To compare the changes in serum levels of total calcium after 12 months of treatment in the two groups (standard supplementationm with calcium and vitamin d vs Synostea®)
Time frame: 12 months
Evaluation of the differences in serum levels of parathyroid hormone betweeen groups after 12 months
To compare the changes in serum levels of total calcium after 12 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 12 months
Evaluation of the differences in serum levels of bone alkaline phosphatase betweeen groups after 12 months
To compare the changes in serum levels of bone alkaline phosphatase after 12 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 12 months
Evaluation of the differences in serum levels of C-terminal telopeptide of type I collagen betweeen groups after 12 months
To compare the changes in serum levels of C-terminal telopeptide of type I collagen (CTX) after 12 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 12 months
Evaluation of the differences in 24-hour calciuria levels betweeen groups after 12 months
To compare the changes in 24-hour calciuria levels after 12 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 12 months
Evaluation of the differences in serum levels of total calcium betweeen groups after 6 months
To compare the changes in serum levels of total calcium after 6 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 6 months
Evaluation of the differences in serum levels of parathyroid hormone betweeen groups after 6 months
To compare the changes in serum levels of parathyroid hormone after 6 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 6 months
Evaluation of the differences in serum levels of bone alkaline phosphatase betweeen groups after 6 months
To compare the changes in serum levels of bone alkaline phosphatase after 6 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 6 months
Evaluation of the differences in serum levels of C-terminal telopeptide of type I collagen betweeen groups after 6 months
To compare the changes in serum levels of C-terminal telopeptide of type I collagen (CTX) after 6 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 6 months
Evaluation of the differences in 24-hour calciuria levels betweeen groups after 6 months
To compare the changes in 24-hour calciuria levels after 6 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 6 months
Evaluation of the differences in Lumbar Bone Mineral Density by D-XA between groups
To evaluate difference in the change from baseline in lumbar BMD (Bone Mineral Density) by dual x ray absorptiometry after 12 months between the 2 groups (standard vitamin d and calcium supplementation vs Synostea®)
Time frame: 12 months
Evaluation of the differences in hip fragility score by Radiofrequency Echographic Multi Spectrometry between groups
To evaluate difference in the change from baseline in hip fragility score by Radiofrequency Echographic Multi Spectrometry after 12 months between the 2 groups (standard vitamin d and calcium supplementation vs Synostea®)
Time frame: 12 months
Evaluation of the differences in serum levels of total alkaline phosphatase betweeen groups after 6 months
To compare the changes in serum levels of total alkaline phosphatase after 6 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 6 months
Evaluation of the differences in serum levels of total alkaline phosphatase betweeen groups after 12 months
To compare the changes in serum levels of total alkaline phosphatase after 12 months of treatment in the two groups (standard supplementation with calcium and vitamin d vs Synostea®)
Time frame: 12 months
Evaluation of the differences in treatment adherence betweeen groups after 12 months
To assess the difference in treatment adherence between the two groups (standard supplementation with calcium and vitamin d vs Synostea®), evaluated using questionnaires created specifically for the study after 12 months.
Time frame: 12 months
Evaluation of the differences in treatment adherence betweeen groups after 6 months
To assess the difference in treatment adherence between the two groups (standard supplementation with calcium and vitamin d vs Synostea®), evaluated using questionnaires created specifically for the study after 6 months.
Time frame: 6 months
Plan to share: Yes — IPD will be published in GARRbox
Time frame: Data will be available after study publication
Access criteria: Data will be available for free
Data sharing details ↗ · gbox.garr.it
Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 24 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regina Elena Cancer Institute